Kirkland and Wachtell steer GSK/Pfizer joint venture
Credit: iStock/William-Barton
Pharmaceutical giants GlaxoSmithKline and Pfizer announced their plans to combine the companies’ consumer health businesses in a deal valued at approximately £9.8 billion (€10.8 billion).
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now